Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions highlight the unexpected results of torcetrapib, with multiple posts mentioning its correlation with a 58% increase in mortality despite achieving favorable changes in cholesterol levels. Phrases like 'increased risk of mortality' and references to 'previous trials' indicate a strong analytical tone, underscoring the seriousness of the findings. Participants frequently cite statistics, such as the effect of the drug on HDL and LDL levels, generating a conversation that emphasizes the study's crucial implications for cardiovascular medicine.
The majority of discussions reflect a consensus regarding the dangerous implications of torcetrapib, showing strong agreement on its negative outcomes.
Participants demonstrate a high level of curiosity and relevance to the topic, indicating that the publication has stirred significant interest.
Many discussions delve deeply into the study's findings, including specific statistics and references to similar studies, indicating substantial engagement with the material.
There is a clear perception that this publication has high importance due to its implications for patient safety and treatment protocols.
Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% higher rate. https://t.co/svxx04ZTPJ
Torcetrapib was worse. Though it lowered LDL by 25% and increased HDL by 72%, patients had a 58% higher death rate. https://t.co/svxx04IQNJ
A previous drug designed to do the same thing, torcetrapib, resulted in a 58% increased death rate. https://t.co/F3vRexvCTi
2/2 Treating a lab number is all Torcetrapib did. Same goes for statins. It's for idiots. Sort out your diet so as to live within the limits of your own personal level of insulin resistance and leave your lipids in peace. https://t.co/GJNXpZhsgE
Gosto do exemplo do torcetrapib para argumentar contra o mecanicismo: um fármaco que aumentava o HDL em >70% e reduzia o LDL EM 25%, mesmo assim, resultou em maior mortalidade. https://t.co/VwSqPzTPMf
"HDL is good cholesterol, LDL is bad" So >HDL and <LDL should be better? Wrong No drugs increasing HDL has seen light of day This one in (Pfizer) 2006 stopped when "an imbalance of mortality and cardiovascular events" inspite of >HDL, <LDL https://t.co/MzabMXqvde https://t.co/O7suHa84Jc https://t.co/YYQqCbr47O
In this video, Dr. Sten Ekberg's cholesterol claims are critically analyzed against scientific evidence. Bempedoic acid, an ATP citrate lyase inhibitor, effectively reduces LDL cholesterol with fewer side effects…
This video explores the misconception that lowering cholesterol with niacin reduces cardiovascular risk. Although niacin improves lipid profiles, studies show it doesn't significantly decrease major cardiovascular…
This video explores the complex roles of HDL and LDL cholesterol in heart health. It discusses findings from research indicating that higher HDL levels via drugs may not reduce heart disease risk, highlighting concerns…
Prof. Dr. Stephen Nicholls presents the BROOKLYN study data on obicetrapib's effects in patients with heterozygous familial hypercholesterolemia, evaluating outcomes alongside maximum tolerated lipid-modifying…
Across major outcome trials that pharmacologically raised HDL-C (torcetrapib, dalcetrapib, niacin ± laropiprant), cardiovascular events were not reduced https://t.co/Vttl43gSkd https://t.co/yNNfHLCFxi https://t.co/wAT1juHIwF https://t.co/aQdYdFSLb6 https://t.co/cUSC19T2YU
RT @LDLSkeptic: @MohammedAlo @robt_heartdoc @BuffJones2 @KetoFiveO @Heartflow @realDaveFeldman @KenDBerryMD @copsandcampers @Sgtjunehawkins…
@MohammedAlo @robt_heartdoc @BuffJones2 @KetoFiveO @Heartflow @realDaveFeldman @KenDBerryMD @copsandcampers @Sgtjunehawkins How about Torceptrapib? https://t.co/sycSMHOm0K
RT @sanchak74: "HDL is good cholesterol, LDL is bad" So >HDL and <LDL should be better? Wrong No drugs increasing HDL has seen light of…
RT @sanchak74: "HDL is good cholesterol, LDL is bad" So >HDL and <LDL should be better? Wrong No drugs increasing HDL has seen light of…
RT @sanchak74: "HDL is good cholesterol, LDL is bad" So >HDL and <LDL should be better? Wrong No drugs increasing HDL has seen light of…
RT @sanchak74: "HDL is good cholesterol, LDL is bad" So >HDL and <LDL should be better? Wrong No drugs increasing HDL has seen light of…
RT @sanchak74: "HDL is good cholesterol, LDL is bad" So >HDL and <LDL should be better? Wrong No drugs increasing HDL has seen light of…
"HDL is good cholesterol, LDL is bad" So >HDL and <LDL should be better? Wrong No drugs increasing HDL has seen light of day This one in (Pfizer) 2006 stopped when "an imbalance of mortality and cardiovascular events" inspite of >HDL, <LDL https://t.co/MzabMXqvde https://t.co/O7suHa84Jc https://t.co/YYQqCbr47O
@jibtie @NutritionMadeS3 https://t.co/mNl98peNUd SFA RCTs make it clear that increasing LDLc does not increase mortality https://t.co/LrurwG05st Torcetrapib is a drug that reduced LDLc and increased mortality https://t.co/5UOn33ZMHn hsCRP predicts mortality better than LDLc in statin trials
@MohammedAlo Fasle. Torcetrapib lowered cholestoral and INCREASED mortality in this RCT https://t.co/LrurwG05st https://t.co/4e64qvTE3k
@Rico_apoach Boaf, en association causale ça parle de "blood lipid profile". Or le HDL n'est pas vraiment cardioprotecteur, contrairement à ce qu'on a longtemps pensé. https://t.co/ooG0pDt64Q https://t.co/WVFlwkopR9
@jimeekay @toadmeister Also https://t.co/WJvKSi3KO3 https://t.co/kFqiymNSL9
@aravindmc @a_nineties 3/3 https://t.co/WJvKSi3KO3 The deaths are detailed in Tables 3 & 4 incl many “Sudden Death”s but I can’t find the definition used for that.
@DanClintonRN not correct Dan - drugs in RCTs have been shown to increase death, e.g., torcetrapib vs placebo https://t.co/YLM7PMIOmr and anti-arrhythmics in the CAST-1 are 2 examples it required statistical significance to show these drugs were harmful. You're not making an impact when you
RT @Mangan150: Torcetrapib was worse. Though it lowered LDL by 25% and increased HDL by 72%, patients had a 58% higher death rate. https:…
Effects of torcetrapib in patients at high risk for coronary events - PubMed https://t.co/W9jRCOmvnW
RT @Mangan150: Torcetrapib was worse. Though it lowered LDL by 25% and increased HDL by 72%, patients had a 58% higher death rate. https:…
RT @Mangan150: Torcetrapib was worse. Though it lowered LDL by 25% and increased HDL by 72%, patients had a 58% higher death rate. https:…
RT @Mangan150: Torcetrapib was worse. Though it lowered LDL by 25% and increased HDL by 72%, patients had a 58% higher death rate. https:…
Torcetrapib was worse. Though it lowered LDL by 25% and increased HDL by 72%, patients had a 58% higher death rate. https://t.co/svxx04IQNJ
Lowering LDL-#cholesterol 25% skyrocketed mortality so much trial ended prematurely (RCT: n=15,067) –After 12 months on torcetrapib, HDL up 72.1% & LDL down 24.9%. CV events (HR=1.25; 1.09/1.44; P=.001) & all-cause mortality (HR=1.58; 1.14/2.19; P=.006) up https://t.co/yaDUXUNZ0N
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
@CarnalDancer @pjungar @MarkBski HDL probably doesn't have an effect on CVD risk though. When it's been raised via drugs it doesn't have a protective effect: https://t.co/YjnjnmRWOr
See ILLUMINATE trial with torcetrapib https://t.co/Uu62tu8zG5
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @AnaCarolPecanha: Gosto do exemplo do torcetrapib para argumentar contra o mecanicismo: um fármaco que aumentava o HDL em >70% e reduzia…
Gosto do exemplo do torcetrapib para argumentar contra o mecanicismo: um fármaco que aumentava o HDL em >70% e reduzia o LDL EM 25%, mesmo assim, resultou em maior mortalidade. https://t.co/VwSqPzTPMf
@leandrotessler Problema é que prova de conceito ñ basta para incorporação de uma tecnologia pelo sistema de saúde. Dados clínicos sólidos são necessários. Se não fosse isso, estaríamos usando torcetrapib p tratar dislipidemia, afinal ele “aumentava o colesterol bom”. https://t.co/nLLuNguocw
@DumazelSilvere 2) des médicaments qui augmentent le HDL (jusqu'à +72% !) ne diminuent pas la mortalité cardiaque (au contraire meme) https://t.co/71TLsmSf9G
@ProfSNicholls @pnatarajanmd @atvbahajournals @MonashUni @HarvardChanSPH @CircAHA Today we have answers “Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism.Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition” https://t.co/Wsk0geeeWr https://t.co/QogHBQ6YKi
RT @almucastro01: ILLUMINATE: https://t.co/nFz4qokmVY ACCELERATE: https://t.co/DWTl6WJzHV https://t.co/9k3nTKf73Z
RT @almucastro01: ILLUMINATE: https://t.co/nFz4qokmVY ACCELERATE: https://t.co/DWTl6WJzHV https://t.co/9k3nTKf73Z
ILLUMINATE: https://t.co/nFz4qokmVY ACCELERATE: https://t.co/DWTl6WJzHV https://t.co/9k3nTKf73Z
RT @redGDPS: El código genético …. rs1333458 Clinical utilities of this knowledge ✅ Mendelian randomization: causal biomarkers. HDL-c (To…
RT @redGDPS: El código genético …. rs1333458 Clinical utilities of this knowledge ✅ Mendelian randomization: causal biomarkers. HDL-c (To…
El código genético …. rs1333458 Clinical utilities of this knowledge ✅ Mendelian randomization: causal biomarkers. HDL-c (Torcetrapib) Voight B, et al. Lancet 2012;380:572-80. https://t.co/B6o1nJTmcA Barter PJ et al. NEJM 2007;357:2109-22 https://t.co/oEGhhswLCD https://t.co/QH0atptJUG
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @hdh150: في دراسة على دواء Torcetrapib ، وهو دواء يخفض الدهون في الدم وجد انه رفع النافع، HDL بنسبة 72٪ وخفض الضار LDL بنسبة 25٪. تم ا…
في دراسة على دواء Torcetrapib ، وهو دواء يخفض الدهون في الدم وجد انه رفع النافع، HDL بنسبة 72٪ وخفض الضار LDL بنسبة 25٪. تم انهاء الدراسة قبل نهايتها بسبب ارتفاع الوفيات والفشل الذريع للدواء فلسوء الحظ ، مات المرضى بمعدل أعلى بنسبة 58٪. https://t.co/K1UrgNol8h
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
RT @Mangan150: Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% high…
Torcetrapib, a lipid-lowering drug, increased HDL by 72% and lowered LDL by 25%. Unfortunately, patients died at a 58% higher rate. https://t.co/svxx04ZTPJ
@vegansie @POhukainen https://t.co/QLY8SAKZAB "Effects of torcetrapib in patients at high risk for coronary events." Dropped LDL by 24%, proportional 25% increase in CVD events... Linear association in the study.
RT @holmanm: 2/2 Treating a lab number is all Torcetrapib did. Same goes for statins. It's for idiots. Sort out your diet so as to live wit…
RT @holmanm: 2/2 Treating a lab number is all Torcetrapib did. Same goes for statins. It's for idiots. Sort out your diet so as to live wit…
2/2 Treating a lab number is all Torcetrapib did. Same goes for statins. It's for idiots. Sort out your diet so as to live within the limits of your own personal level of insulin resistance and leave your lipids in peace. https://t.co/GJNXpZhsgE
RT @xrtGenomics: @VPrasadMDMPH @VincentRK @rrichardh @oncology_bg CTEP inhibitors for HDL (e.g. Torcetrapib) -- drugs raised surrogate; but…
RT Mangan150: A previous drug designed to do the same thing, torcetrapib, resulted in a 58% increased death rate. https://t.co/rXQ9CsCHsl
RT @Mangan150: A previous drug designed to do the same thing, torcetrapib, resulted in a 58% increased death rate. https://t.co/F3vRexvCTi
@MilesHighLife https://t.co/3OSpZagpk3
RT @Mangan150: A previous drug designed to do the same thing, torcetrapib, resulted in a 58% increased death rate. https://t.co/F3vRexvCTi
RT @Mangan150: A previous drug designed to do the same thing, torcetrapib, resulted in a 58% increased death rate. https://t.co/F3vRexvCTi
A previous drug designed to do the same thing, torcetrapib, resulted in a 58% increased death rate. https://t.co/F3vRexvCTi